Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Fine-Tuning = 72%.

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Jun 01, 2023 1:16pm

257 Views

Post# 35475232

RE:RE:Fine-Tuning = 72%.

wildbird is not writing about the CR rate at 450 days - he's writing about the CR results of the 3 patients at 270 days, the 7 at 180 days and the 4 at 90 days. 10 out of these 14 patients are CR - that's 71%

You have to look at the recent swimmer's plot to appreciate what he's saying. The results at 270 days and below are predominantly CR.

N0taP00p wrote: @wildbird1 - how can your CR number be more than twice that published by Theralase. Even the KM curve projection doesn't cross 35% at 450 days.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland